Icosavax, Inc.
Funding rounds
2 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Mar 2021 | $100 M | No. 2 | $50 to $250 million | equity | SEC | |
| Aug 2019 | $30 M | No. 1 | $10 to $50 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Icosavax, Inc. chose not to state its revenue in its newest notice of a funding round (Apr 2021).
SEC Form D · Apr 2021
The industry group it chose in its notices: Biotechnology.
SEC Form D · Apr 2021
That is all the official record says: Icosavax, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
12 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Adams Street Partners LLC | Fund or asset manager | not stated | not stated | Held Series A-1 and B-1 preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Cormorant Asset Management, LP | Fund or asset manager | not stated | not stated | Held Series B-1 preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Cormorant Global Healthcare Master Fund, LP | Fund or asset manager | not stated | not stated | Held Series B-1 preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Cormorant Private Healthcare Fund III LP | Fund or asset manager | not stated | not stated | Held Series B-1 preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| NanoDimension III GP Limited Partnership | Fund or asset manager | not stated | not stated | Held Series A-1 and B-1 preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| NanoDimension III, L.P. | Fund or asset manager | not stated | not stated | Held Series A-1 and B-1 preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| NanoDimension III Management Ltd | Fund or asset manager | not stated | not stated | Held Series A-1 and B-1 preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Qiming U.S. Healthcare Fund II, L.P. | Fund or asset manager | not stated | not stated | Held Series A-1 and B-1 preferred stock, 10% owner, director (Form 3, 2021) | SEC Form 3 |
| Qiming U.S. Healthcare GP II, LLC | Other | not stated | not stated | Held Series A-1 and B-1 preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| RA Capital Healthcare Fund LP | Fund or asset manager | not stated | not stated | Held Series B-1 preferred stock, 10% owner, director (Form 3, 2021) | SEC Form 3 |
| Ra Capital Management, L.P. | Fund or asset manager | not stated | not stated | Held Series B-1 preferred stock, 10% owner, director (Form 3, 2021) | SEC Form 3 |
| RA Capital Nexus Fund II, L.P. | Fund or asset manager | not stated | not stated | Held Series B-1 preferred stock, 10% owner, director (Form 3, 2021) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 36 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Adam K. Simpson | President and Chief Executive Officer | Apr 2021 |
| Cassia A. Cearley | Treasurer, Chief Business Officer | Apr 2021 |
| Charles A. Richardson | Senior Vice President, Technical Operations | Apr 2021 |
| Douglas A. Holtzman | Chief Scientific Officer and Secretary | Apr 2021 |
| Niranjan A. Kanesa-thasan | Chief Medical Officer | Apr 2021 |
| Adam K. Simpson | President and Chief Executive Officer | Apr 2021 |
| Eric A. Moessinger | Director | Apr 2021 |
| Jason A. Hafler | Director | Apr 2021 |
| Mark A. McDade | Director | Apr 2021 |
| Peter A. Kolchinsky | Director | Apr 2021 |
| Tadataka Yamada, M.D. | Chairman of the Board | Apr 2021 |
| Terry A. Gould | Director | Apr 2021 |